Generics And Biosimilars Saved US $445bn In 2023, But Industry Stands At ‘Critical Crossroads’
AAM Released Its Annual Report, Calculating Savings Brought In By Generics And Biosimilars
Despite bringing more and more savings to the US healthcare system, generics and biosimilars are facing unsustainable practices and an uncertain market.
